FCGR3A and neoplasm: To properly evaluate the synergistic effect of combinatorial therapy in expanded PBNK cells with a different ratio of CD16 alleles (154/3G8), we explored the tumor cytotoxicity of PBNK cells bearing a high (0.46) and a low ratio (0.24) against the MM cell line RPMI 8226 after mixing with the approved mAb Daratumumab.